Trials / Terminated
TerminatedNCT05000450
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti- BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Allogene Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | ALLO-605 | ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product |
| BIOLOGICAL | ALLO-647 | ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen |
| DRUG | Fludarabine | Chemotherapy for lymphodepletion |
| DRUG | Cyclophosphamide | Chemotherapy for lymphodepletion |
Timeline
- Start date
- 2021-06-06
- Primary completion
- 2023-10-11
- Completion
- 2023-10-11
- First posted
- 2021-08-11
- Last updated
- 2024-06-28
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05000450. Inclusion in this directory is not an endorsement.